Copyright
©2014 Baishideng Publishing Group Co., Limited. All rights reserved.
Coenzyme Q10 in neurodegenerative disorders: Potential benefit of CoQ10 supplementation for multiple system atrophy
Hiroshi Takahashi, Kotaro Shimoda, Department of Neurology, National Hospital Organization, Tottori Medical Center, Tottori 689-0203, Japan
Author contributions: Both authors contributed to the writing of this manuscript and have read and approved the final version.
Correspondence to: Hiroshi Takahashi, MD, PhD, Department of Neurology, National Hospital Organization, Tottori Medical Center, 876 Mitsu, Tottori 689-0203, Japan. hiroshi@tottori-iryo.hosp.go.jp
Telephone: +81-857-591111 Fax: +81-857-591589
Received: September 26, 2013
Revised: December 3, 2013
Accepted: April 9, 2014
Published online: March 28, 2014
Revised: December 3, 2013
Accepted: April 9, 2014
Published online: March 28, 2014
Core Tip
Core tip: Recently, multiple system atrophy (MSA), relatively common in adult-onset neurodegenerative diseases, was shown to be linked to mutations in the COQ2 gene, one of the genes involved in the Coenzyme Q10 (CoQ10) biosynthesis pathway. Neurologists so far have not paid much attention to CoQ10 because primary CoQ10 deficiency caused by mutations in the CoQ10 synthesizing genes is very rare. The most important message is that primary CoQ10 deficiency is treatable with exogenous CoQ10 and that oral CoQ10 supplementation might be also beneficial for patients with MSA.